
|Slideshows|March 23, 2017
ACC 2017: Late-Breaking Clinical Trials
Author(s)Samantha J. Peterson
Research includes safety of digoxin with atrial fibrillation, comparison of cerebral embolic protection devices, and cerebral microbleed triggers.
Advertisement
Presentations during the Late-Breaking Clinical Trials session at the American College of Cardiology’s Annual Scientific Sessions included a safety investigation of digoxin use in patients with atrial fibrillation, a study of two embolic protection devices and their abilities to prevent stroke and brain infarcts, and possible triggers of cerebral microbleeds during transacatheter aortic valve replacement.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
The Future of Targeted Therapy in CIDP
2
FDA Grants Fast Track Designation to Safusidenib for IDH1-Mutant Glioma
3
FDA Clears Roche's Single-Biomarker Elecsys pTau217 Blood Test for Alzheimer Disease
4
FDA Places RGX-121 Gene Therapy for MPS II on Clinical Hold
5

















